vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.1倍（$196.9M vs $183.1M），Pacira BioSciences, Inc.同比增速更快（5.1% vs -1.8%），Pacira BioSciences, Inc.自由现金流更多（$43.5M vs $24.6M），过去两年Pacira BioSciences, Inc.的营收复合增速更高（8.5% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
AMPH vs PCRX — 直观对比
营收规模更大
PCRX
是对方的1.1倍
$183.1M
营收增速更快
PCRX
高出7.0%
-1.8%
自由现金流更多
PCRX
多$18.9M
$24.6M
两年增速更快
PCRX
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $196.9M |
| 净利润 | $24.4M | — |
| 毛利率 | 46.8% | 79.5% |
| 营业利润率 | 19.4% | 1.2% |
| 净利率 | 13.3% | — |
| 营收同比 | -1.8% | 5.1% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPCRX
| Q4 25 | $183.1M | $196.9M | ||
| Q3 25 | $191.8M | $179.5M | ||
| Q2 25 | $174.4M | $181.1M | ||
| Q1 25 | $170.5M | $168.9M | ||
| Q4 24 | $186.5M | $187.3M | ||
| Q3 24 | $191.2M | $168.6M | ||
| Q2 24 | $182.4M | $178.0M | ||
| Q1 24 | $171.8M | $167.1M |
净利润AMPHPCRX
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $5.4M | ||
| Q2 25 | $31.0M | $-4.8M | ||
| Q1 25 | $25.3M | $4.8M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-143.5M | ||
| Q2 24 | $37.9M | $18.9M | ||
| Q1 24 | $43.2M | $9.0M |
毛利率AMPHPCRX
| Q4 25 | 46.8% | 79.5% | ||
| Q3 25 | 51.4% | 80.9% | ||
| Q2 25 | 49.6% | 77.4% | ||
| Q1 25 | 50.0% | 79.7% | ||
| Q4 24 | 46.5% | 78.7% | ||
| Q3 24 | 53.3% | 76.9% | ||
| Q2 24 | 52.2% | 75.1% | ||
| Q1 24 | 52.4% | 71.6% |
营业利润率AMPHPCRX
| Q4 25 | 19.4% | 1.2% | ||
| Q3 25 | 13.2% | 3.5% | ||
| Q2 25 | 24.2% | 4.7% | ||
| Q1 25 | 21.9% | 1.2% | ||
| Q4 24 | 24.2% | 13.2% | ||
| Q3 24 | 29.8% | -82.8% | ||
| Q2 24 | 30.3% | 15.9% | ||
| Q1 24 | 27.9% | 7.9% |
净利率AMPHPCRX
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 3.0% | ||
| Q2 25 | 17.8% | -2.7% | ||
| Q1 25 | 14.8% | 2.8% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -85.1% | ||
| Q2 24 | 20.8% | 10.6% | ||
| Q1 24 | 25.1% | 5.4% |
每股收益（稀释后）AMPHPCRX
| Q4 25 | $0.51 | $0.05 | ||
| Q3 25 | $0.37 | $0.12 | ||
| Q2 25 | $0.64 | $-0.11 | ||
| Q1 25 | $0.51 | $0.10 | ||
| Q4 24 | $0.74 | $0.38 | ||
| Q3 24 | $0.78 | $-3.11 | ||
| Q2 24 | $0.73 | $0.39 | ||
| Q1 24 | $0.81 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $238.4M |
| 总债务越低越好 | $608.7M | $372.2M |
| 股东权益账面价值 | $788.8M | $693.1M |
| 总资产 | $1.6B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资AMPHPCRX
| Q4 25 | $282.8M | $238.4M | ||
| Q3 25 | $276.2M | $246.3M | ||
| Q2 25 | $231.8M | $445.9M | ||
| Q1 25 | $236.9M | $493.6M | ||
| Q4 24 | $221.6M | $484.6M | ||
| Q3 24 | $250.5M | $453.8M | ||
| Q2 24 | $217.8M | $404.2M | ||
| Q1 24 | $289.6M | $325.9M |
总债务AMPHPCRX
| Q4 25 | $608.7M | $372.2M | ||
| Q3 25 | $608.6M | $376.7M | ||
| Q2 25 | $607.7M | $580.5M | ||
| Q1 25 | $603.9M | $583.4M | ||
| Q4 24 | $601.6M | $585.3M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHPCRX
| Q4 25 | $788.8M | $693.1M | ||
| Q3 25 | $776.7M | $727.2M | ||
| Q2 25 | $757.5M | $757.8M | ||
| Q1 25 | $751.3M | $798.5M | ||
| Q4 24 | $732.3M | $778.3M | ||
| Q3 24 | $727.7M | $749.6M | ||
| Q2 24 | $713.3M | $879.3M | ||
| Q1 24 | $672.4M | $892.2M |
总资产AMPHPCRX
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.6B |
负债/权益比AMPHPCRX
| Q4 25 | 0.77× | 0.54× | ||
| Q3 25 | 0.78× | 0.52× | ||
| Q2 25 | 0.80× | 0.77× | ||
| Q1 25 | 0.80× | 0.73× | ||
| Q4 24 | 0.82× | 0.75× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $43.7M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $43.5M |
| 自由现金流率自由现金流/营收 | 13.4% | 22.1% |
| 资本支出强度资本支出/营收 | 4.5% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $136.7M |
8季度趋势，按日历期对齐
经营现金流AMPHPCRX
| Q4 25 | $32.9M | $43.7M | ||
| Q3 25 | $52.6M | $60.8M | ||
| Q2 25 | $35.6M | $12.0M | ||
| Q1 25 | $35.1M | $35.5M | ||
| Q4 24 | $29.0M | $33.1M | ||
| Q3 24 | $60.0M | $53.9M | ||
| Q2 24 | $69.1M | $53.2M | ||
| Q1 24 | $55.3M | $49.1M |
自由现金流AMPHPCRX
| Q4 25 | $24.6M | $43.5M | ||
| Q3 25 | $47.2M | $57.0M | ||
| Q2 25 | $25.0M | $9.3M | ||
| Q1 25 | $24.4M | $26.9M | ||
| Q4 24 | $16.6M | $31.0M | ||
| Q3 24 | $46.2M | $49.8M | ||
| Q2 24 | $63.1M | $51.6M | ||
| Q1 24 | $46.5M | $46.3M |
自由现金流率AMPHPCRX
| Q4 25 | 13.4% | 22.1% | ||
| Q3 25 | 24.6% | 31.7% | ||
| Q2 25 | 14.3% | 5.1% | ||
| Q1 25 | 14.3% | 15.9% | ||
| Q4 24 | 8.9% | 16.6% | ||
| Q3 24 | 24.1% | 29.6% | ||
| Q2 24 | 34.6% | 29.0% | ||
| Q1 24 | 27.1% | 27.7% |
资本支出强度AMPHPCRX
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 2.2% | ||
| Q2 25 | 6.1% | 1.5% | ||
| Q1 25 | 6.3% | 5.1% | ||
| Q4 24 | 6.7% | 1.1% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 0.9% | ||
| Q1 24 | 5.1% | 1.7% |
现金转化率AMPHPCRX
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 11.20× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 7.37× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 2.82× | ||
| Q1 24 | 1.28× | 5.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
